Hence, the importance of dornase alfa's mode of mechanism of breaking down extracellular DNA to decrease the viscosity of mucus.
Dornase alfa is administered through inhalation, during which minimal systemic absorption occurs.
Alfa - Dornase
alfa reduces extracellular DNA and binding polymers to reduce viscosity.
6 years old, the mean lung function at baseline was 92% of the predicted normal value of FEV1, and the use of concomitant medications included inhaled antibiotics (37%), dornase
alfa (Pulmozyme([R])) (77%) and oral macrolide antibiotics (40%).
Auric 10 Combination Neomicinum + Bacitracinum 11 Combination Oximed 12 Diclofenacum 50 Mg Miscellaneous 13 Liv 52 14 Dobutaminum 15 Dornase
Alfa 1Mg Ml 16 Epinephrinum 1 Mg 1 Ml 17 Ertapenemum 18 Esomeprazolum Nij.
Pulmoxen, for the treatment of cystic fibrosis: Pre-clinical research has been completed and a unique high-production eukaryotic strain was created for the producer of a fused protein dornase
Food and Drug Administration (FDA), including dornase
alfa, tobramycin, macrolides and digestive enzymes, will be permitted in the trial.
8 sgb v into finished products containing the active ingredient dornase
To ensure that results from this trial are predictive of efficacy in heavily treated cystic fibrosis patient and consistent with current clinical practice, the study will enroll patients that have recently received multiple courses of inhaled antibiotics and in most cases are receiving concomitant medication such as dornase
alpha, azithromycin and hypertonic saline.
alfa, high-dose ibuprofen and pancreatic enzyme), FEV(1) % predicted, and use of medical resources.
To ensure that results from this trial were as predictive as possible for the future Phase 3 program and consistent with current clinical practice, the study enrolled patients that had recently received multiple courses of inhaled antibiotics and in most cases were receiving concomitant medication such as dornase
alpha, azithromycin and hypertonic saline that have been shown in previous studies to improve lung function and/or reduce exacerbations.
The key secondary endpoint of the trial was to assess whether Bronchitol further improves lung function in patients already being treated with the most commonly used CF therapeutic, dornase